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Introduction: Crohn’s disease (CD) is a chronic inﬂ  ammatory bowel disease characterized 
by a relapsing-remitting course with trans-mural inﬂ  ammation of potentially any section of the 
digestive tract. Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, 
IgG1 monoclonal antibody that binds with high afﬁ  nity and speciﬁ  city to human TNF-alpha, 
thus modulating its biologic functions and its proinﬂ  ammatory effects.
Aims: To review the available data on ADA in CD for biological properties, efﬁ  cacy, and 
safety.
Methods: Electronic searches were conducted using the Pubmed and SCOPUS databases from 
the earliest records to April 2008. The search terms used were “adalimumab”, “anti-TNF”, 
“TNF-alpha”, “biologicals”, “inﬂ  ammatory bowel disease”, and “Crohn’s disease”. Reference 
lists of all relevant articles were searched for further studies.
Results: Available studies suggest that ADA has the potential to induce and maintain clinical 
response and remission in moderate-severe CD, both in anti-TNF-naïve patients and in subjects 
who lost their response and/or became intolerant to inﬂ  iximab (IFX). ADA seems also effective 
in maintaining corticosteroid-free remission and obtaining complete ﬁ  stula closure (although 
no speciﬁ  c randomized trials are available). No concomitant immunosuppressors seem to be 
necessary. Side effects appear similar to IFX, while site-injection reactions are frequent and 
speciﬁ  c. Data on immunogenicity and its clinical impact are uncertain.
Conclusions: ADA appears to be effective in inducing and maintain clinical remission in CD, 
including patients not manageable with IFX. Successive clinical practice and further on going 
trials will conﬁ  rm a positive role for ADA as a new anti-TNF treatment in CD. The impact on 
clinical management or on resources should be more studied.
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Introduction
Crohn’s disease (CD) is a chronic inﬂ  ammatory bowel disease (IBD) characterized by 
a relapsing-remitting course with trans-mural inﬂ  ammation of potentially any section 
of the digestive tract, leading to various intestinal (internal and external ﬁ  stulas, 
intestinal strictures, abdominal and perianal abscesses) and extra-intestinal manifes-
tations (Baumgart and Sandborn 2007). Its incidence is 5 out of 100,000 people and 
its prevalence is estimated to be 30 to 50 out of 100,000 people in Western countries. 
The disease represents an important public health problem, as it tends to affect young 
people and have a chronic course affecting quality of life, social activities and working 
abilities.
While the etiology remains unknown, the understanding of the molecular 
mediators and mechanisms of tissue injury have greatly advanced (Ardizzone and 
Bianchi Porro 2005). The disease has been suggested to develop in a genetically 
predisposed subject due to a disregulated immune response to unknown antigens 
(probably environmental or infective, including endogenous microﬂ  ora), resulting 
in continuous immune-mediated inﬂ  ammation (Ardizzone and Bianchi Porro 2002; 
Baumgart and Carding 2007).Biologics: Targets & Therapy 2008:2(4) 764
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In the absence of a well-defined etiology, current 
treatment protocols are aimed at modulating, by various 
approaches, the complex inﬂ  ammatory events leading to 
intestinal injury (Travis et al 2006). However, the treat-
ments currently available cannot be considered curative 
and, even today, up to 70% of patients undergo surgery due 
to complications of the disease; moreover, an important 
subgroup of patients fail to show a signiﬁ  cant beneﬁ  t from 
conventional treatments, thus delineating the particular 
scenario of refractory CD and the need for novel therapeutic 
strategies (Cassinotti et al 2008).
Current therapeutic management of CD is usually 
defined as a “step-up” strategy, based on the use of 
drugs with a gradually increasing strength of action, 
according to disease extension, severity (mild, moderate 
or severe) and activity (induction vs maintenance therapy), 
disease pattern (inﬂ  ammatory, penetrating-ﬁ  stulizing or 
stricturing), response to current or prior medications, and 
the presence of complications (Ardizzone and Bianchi Porro 
2005). Available treatments aim at inducing remission, 
preventing relapses, improving quality of life and addressing 
complications. Conventional drugs used in CD consist 
of aminosalicylates, corticosteroids, immunosuppressors 
[azathioprine (AZA), 6-mercaptopurine (6MP), methotrexate 
(MTX)] and immunomodulators such as antagonists of 
tumor necrosis factor (TNF)-alpha, ie, inﬂ  iximab (IFX) and 
adalimumab (ADA).
The proinflammatory cytokine TNF-alpha is a key 
mediator of inﬂ  ammation associated with CD (Breese and 
McDonald 1995). TNF-alpha is a homotrimeric protein that 
exists in both transmembrane and soluble forms, the latter 
resulting from proteolytic cleavage and release. Its biological 
activities include the induction of proinﬂ  ammatory cytokines 
such as interleukin (IL)-1 and IL-6, activation of neutrophils, 
and enhancement of leukocyte migration (Papadakis and 
Targan 2000). Increased levels of TNF-alpha are found in 
diseased areas of the bowel wall, and in the blood and stools 
of patients with CD, compared with normal controls (Braegger 
et al 1992; Murch et al 1993; Reinecker et al 1993).
With the approval in 1998 of IFX, the ﬁ  rst anti-TNF agent 
studied in CD, the treatment of this disease was dramatically 
changed. IFX provided swift relief with a long duration of 
beneﬁ  t to a sizeable subgroup of CD whose disease was 
unresponsive to other medications. Since its initial approval, 
indications for its use have included ﬁ  stulazing disease, 
maintenance of remission, pediatric CD and ulcerative colitis. 
Over the past decade, knowledge about the use and safety of 
IFX has expanded considerably.
IFX is an intravenously administered chimeric monoclonal 
antibody of the immunoglobulin (Ig) G1 subclass and 
comprises 75% human and 25% mouse sequences (Figure 1). 
The presence of this murine component provides a source of 
potential immunogenicity for humans. In facts, chimeric anti-
bodies, such as IFX, can induce strong human anti-chimeric 
antibody (HACA) responses when administered to patients; 
these are referred to as antibodies to inﬂ  iximab (ATI) and 
have been detected in 30% to 61% of patients treated with 
episodic IFX treatment compared with 7% to 10% of patients 
on scheduled IFX regimen (Baert et al 2003; Farrell et al 2003; 
Hanauer et al 2004). In the treatment of chronic disorders such 
as CD, for which large doses (or repeat dosing) of monoclonal 
antibodies may be required, the incidence of HACA has been 
associated with a shortening of the half-life of the drug in serum 
and a secondary loss of efﬁ  cacy, in addition to potential infusion 
reactions, kidney damage and serum sickness.
In the attempt to reduce the immunogenic responses 
induced by chimeric antibodies, new approaches tried to 
remove all mouse-derived sequences, hence to develop fully 
human monoclonal antibodies. This was the case for ADA, 
the ﬁ  rst fully human antibody to be approved.
First named D2E7, ADA (Humira®; Abbott Laboratories, 
Abbott Park, IL, USA) is a subcutaneously administered, 
recombinant, fully human, IgG1 monoclonal antibody 
that binds with high affinity and specificity to human 
TNF-alpha, thus modulating its biologic functions (Plosker 
and Lyseng-Williamson 2007).
The drug is available in a number of countries, includ-
ing the US and EU countries, where it is approved for use 
in rheumatoid arthritis (RA), psoriatic arthritis, ankylosing 
spondylitis and, more recently, CD.
This review will focus on the use of ADA in patients 
with moderate to severe CD. Recent and emerging data from 
clinical trials have demonstrated the efﬁ  cacy of ADA in this 
clinical setting and some considerations can be made at this 
time of its development.
Methods
Electronic searches were conducted using the Pubmed and 
SCOPUS databases from the earliest records to April 2008. 
The search terms used were “adalimumab”, “anti-TNF”, 
“TNF-alpha”, “biologicals”, “inﬂ  ammatory bowel disease”, 
and “Crohn’s disease”. Reference lists of all relevant articles 
were searched for further studies. Of the identiﬁ  ed studies 
only articles published in the English language were selected. 
Relevant abstracts and other material from meetings were 
also included in the analysis. Studies concerning the use Biologics: Targets & Therapy 2008:2(4) 765
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of ADA in other disease, such as RA, were also included 
if interesting information, not yet available in CD, were 
provided.
Pharmacodynamics
ADA is a recombinant, fully human, IgG1 monoclonal 
antibody that binds specifically to TNF-alpha, but not 
lymphotoxin, thereby neutralizing the effect of the cytokine 
by blocking its interaction with p55 and p75 cell surface TNF 
receptors (Tracey et al 2008).
ADA was created using phage display technology 
resulting in an antibody with human derived heavy and light 
chain variable regions and human IgG1:κ constant regions. 
It is considered “fully human” meaning that the coding 
gene sequences do not contain elements cloned from other 
animal species.
ADA is produced in a mammalian cell expression system 
and is puriﬁ  ed by a process that includes speciﬁ  c viral inac-
tivation and removal steps. It consists of 1330 amino acids 
and has a molecular weight of approximately 148 kDa.
ADA affects biologic responses that are regulated 
by TNF-alpha, including changes in the concentra-
tions of adhesion molecules responsible for leukocyte 
migration (eg, ELAM-1, VCAM-1, ICAM-1). In addition 
to neutralizing TNF-alpha, the clinical efﬁ  cacy of ADA in 
CD also appears to involve induction of apoptosis (Shen 
et al 2005, 2006). ADA induced apoptosis of transmembrane 
TNF-positive monocyte and T cells and in a chimeric mouse 
model, with activation of intracellular caspases in vitro, thus 
reﬂ  ecting an outside-to-inside signal transduction through 
transmembrane TNF-alpha. (Shen et al 2005, 2006; Nesbitt 
et al 2007; Mitoma et al 2008). The induction of apoptosis in 
T cells appeared to be concentration-dependent (Chaudhary 
et al 2006). Moreover, ADA was able to inﬂ  uence in vitro 
monocyte cytokine production (down-regulation of IL-10 and 
12) (Shen et al 2005), to inhibit antigen-induced IFN-gamma 
production (Saliu et al 2006), to enhance the production of 
tissue inhibitor of metalloproteinases (TIMP)-1 (Di Sabatino 
et al 2007), and to increase the number and function of 
peripheral blood T regulatory cells (T-regs) from baseline 
in patients with RA (Vigna-Pérez et al 2005).
As bivalent monoclonal antibodies, each ADA molecule 
can bind up to two TNF-alpha molecules simultaneously, 
whereas a single TNF-alpha homotrimer can bind up to 
3 molecules of ADA (Santora et al 2001; Scallon et al 2002). 
These features allow multimeric complexes to form under 
permissive stochiometric conditions.
An in vitro study showed that ADA, like IFX, exerts 
complement-dependent cytotoxicity (CDC) and antibody-
dependent cell-mediated cytotoxicity (ADCC) in transmem-
brane TNF-alpha-expressing T cells (Mitoma et al 2008). 
This is due to its effector IgG1 portion, and cells coated with 
antibody isotypes that ﬁ  x complement and bind Fc receptors 
(such as human IgG1) can activate these responses (Furst 
et al 2006).
In a small substudy of a randomized trial of patients with 
RA, ADA treatment did not signiﬁ  cantly alter the numbers 
of peripheral blood NK cells, monocytes/macrophages, 
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Figure 1 Efﬁ  cacy of adalimumab (ADA) as induction therapy in CLASSIC I trial for Crohn’s disease. Derived from Hanauer et al (2006).
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B cells or major T-cell subsets (Kavanaugh et al 2002). 
In addition, lymphocyte proliferation, DTH reactivity and 
antibody responses to pneumococcal antigen vaccination 
were not altered by ADA treatment, as was not diminished the 
capacity of patients with RA to develop protective antibody 
titers in response to inﬂ  uenza or pneumococcal vaccines 
(Kaine et al 2007).
Pharmacokinetics
In healthy volunteers who received a single dose of 
ADA 40 mg subcutaneously, mean values for peak serum 
concentration (Cmax) and time to achieve Cmax were 4.7 μg/mL 
and 131 hours (5.5 days). Absolute bioavailability after a 
single 40 mg subcutaneous dose of the drug was 64% (Plosker 
and Lyseng-Williamson 2007).
In general, the pharmacokinetic profile of ADA in 
patients with CD appears to be similar to that in patients 
with RA. Various pharmacokinetic analyses in patients with 
RA receiving single doses of ADA 0.25 to 10 mg/kg intrave-
nously have shown that the volume of distribution was 4.7 to 
6 L, systemic clearance was approximately 12 mL/h, and 
mean terminal elimination half-life was about 2 weeks (range 
10–20 days) (Plosker and Lyseng-Williamson 2007).
Pharmacokinetic data on ADA are also available from 
211 patients with moderate to severe CD who participated 
in the CLASSIC-I clinical trial (see below) (Paulson et al 
2005). Patients were randomized to receive placebo or 1 of 
3 subcutaneous ADA induction regimens. Serum ADA 
concentrations were sustained during the 4-week study period 
and increased in a dose-proportional manner.
In patients with CD receiving maintenance therapy with 
ADA 40 mg every other week, mean steady-state trough 
concentrations of the drug were quite 7 μg/mL at week 24 and 
week 56 (Granneman et al 2003).
Concurrent use of MTX reduced ADA apparent clear-
ance by 44% after multiple dose administration in patients 
with RA; current data on the effects of this pharmacokinetic 
interaction with CD are limited to a small number of patients 
and are, therefore, inconclusive, although ADA clearance did 
not appear to be affected by concurrent immunosuppressant 
therapy in this patient population (Garimella et al 2006).
In RA, the presence of nonlinearity in ADA clearance has 
been reported (Granneman et al 2003) and analyses revealed 
that the apparent clearance of ADA increased in the presence 
of anti-ADA antibodies (see below). The combination of 
slow absorption rates after subcutaneous administration, slow 
elimination rates, and the appropriate dosing frequencies of 
ADA yields smooth and uniform concentration – time proﬁ  les 
at steady state, all being desirable qualities in the context of the 
“therapeutic window” paradigm (Nestorov et al 2004).
Efﬁ  cacy
The clinical efficacy of ADA has been evaluated in 
4 pivotal trials involving more than 1400 patients with 
moderate to severe CD. These randomized, double-blind, 
placebo-controlled, multicenter studies include 2 induction 
trials lasting 4 weeks (CLASSIC-I and GAIN) (Hanauer 
et al 2006; Sandborn et al 2007a) and 2 maintenance trials 
(CLASSIC-II and CHARM) lasting 52 and 56 weeks, 
respectively (Sandborn et al 2007b; Colombel et al 2007a). 
ADA was administered subcutaneously in all clinical trials. 
All included patients had moderate to severe disease, as 
deﬁ  ned by a Crohn’s Disease Activity Index (CDAI) of 
220 to 450 (Best et al 1976).
Results of each of these studies, as well as data from other 
uncontrolled reports have shown that ADA can be effective in 
inducing and maintaining clinical response and remission in 
CD, both in anti-TNF-naïve patients and in subjects who lost 
their response and/or became intolerant to IFX. No speciﬁ  c 
trials were designed for ﬁ  stulizing disease, but some data 
have been suggested by subanalyses of the aforementioned 
studies. Finally, all studies describe a signiﬁ  cant improve-
ment in quality of life, as assessed by the IBD-Questionnaire 
(IBD-Q) scores.
Controlled trials offer the best mean to establish clinical 
efﬁ  cacy and to identify the most common side effects of a 
therapy. As well as for any CD drugs, but even more and more 
for those compounds where economical and safety implica-
tions are very important, the risk of an uncritical reception of 
positive results, however modest, should be considered. This 
situation has already occurred with previous compounds, 
including a successful drug such as IFX, although we can 
now beneﬁ  t from a longer period of clinical knowledge 
and use. Firstly, it should be remembered that “statistical 
signiﬁ  cance” does not always reﬂ  ects “clinical signiﬁ  cance”. 
Secondly, in designing a clinical efﬁ  cacy protocol, the need to 
establish adequate therapeutic targets instead of creating any 
surrogates that emphasise otherwise modest results should 
be underlined. Although the use of response rate may be 
more efﬁ  cient in determining drug efﬁ  cacy, it does appear 
to be particularly susceptible to a high placebo effect; in 
this regard, remission rates may be a more appropriate and 
clinically meaningful primary endpoint. Fortunately, most 
of ADA trials have considered clinical remission as their 
primary end-point. Thirdly, it is worthwhile pointing out that 
CDAI, on which most randomized clinical trial of CD have Biologics: Targets & Therapy 2008:2(4) 767
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been based, is not a perfect instrument, being inﬂ  uenced by 
many confounding factors, thus not always reﬂ  ecting the 
real correlation between symptoms and disease activity. 
Other rigorous activity indexes, such as mucosal healing, or 
other important patient-oriented parameters, such as quality 
of life, should be added in future, although their accuracy 
is much debated.
In conclusion, it is our opinion that the main targets for 
any therapy, to be considered indicative of some efﬁ  cacy in 
CD, should be the induction and the maintenance of complete 
remission, and the prevention of adverse events in order to 
improve patient compliance, complication rate, and the need 
for surgery. Some data on ADA according to this view are 
already available, while others need to be added in future.
Randomized clinical trials: induction 
of response and remission
The CLASSIC I (CLinical Assessment of adalimumab Safety 
and efﬁ  cacy Studied as Induction therapy in Crohn’s disease) 
was a phase III, placebo-controlled, dose-ranging induction 
trial, which included 299 patients with moderate to severe 
CD, naïve to anti-TNF therapy, randomized to 1 of 4 induc-
tion regimens at weeks 0 and 2 with ADA and followed 
through week 4 (Hanauer et al 2006).
The 4 induction regimens were: 1) ADA 40 mg at 
week 0 and 20 mg at week 2 (40 mg/20 mg; n = 74); 2) ADA 
80 mg at week 0 and 40 mg at week 2 (80/40; n = 75); 3) ADA 
160 mg at week 0 and 80 mg at week 2 (160/80; n = 76) or 
4) placebo at weeks 0 and 2 (n = 74).
Concurrent therapies for CD, including 5-aminosalicylates, 
corticosteroids and immunosuppressors, were permitted at 
stable dosages.
The primary analysis involved a comparison of the 
two greatest dosage regimens of ADA vs placebo for the 
percentage of patients who achieved clinical remission at 
week 4. Secondary analyses included comparison between 
each ADA dosage group and placebo for the percentage of 
patients with a 70- or 100-point response. A response was 
deﬁ  ned as a CDAI score reduction of 70 points (70-point 
response) or of 100 points (100-point response) from week 0, 
while remission was deﬁ  ned as a CDAI score 150.
Results at week 4 (Figure 1) showed a signiﬁ  cantly 
greater remission rate among patients treated with 
160/80 (36%) or ADA 80/40 (24%) than among those who 
received placebo (12%) (p = 0.004 among the 3 groups). 
There was a linear dose response across the 3 ADA treatment 
groups at week 4 for the endpoints of remission and 100-point 
response, with only the highest dose group (160/80 mg) 
demonstrating statistical significance in the pairwise 
comparisons with placebo: 36% vs 12% for remission 
(p = 0.001) and 50% vs 25% (p = 0.002) for the 100-point 
response; the 70-point response was also signiﬁ  cantly higher 
in the ADA recipients than placebo, both for the 160/80 mg 
dosage (59% vs 37%; p = 0.007) and for the 80/40 mg 
group (59% vs 37%; p = 0.01). The reduction of CDAI from 
baseline was evident as early as week 1. Clinical remis-
sion rates were not inﬂ  uenced by the use of concomitant 
immunosuppressant therapy (Table 1).
Only 11% (32/299) of the randomized patients had 
draining enterocutaneous or perianal ﬁ  stulas at baseline 
and were unevenly distributed across the treatment groups. 
The rates of ﬁ  stula improvement and remission for the 
ADA-treated patients and those receiving placebo were 
not signiﬁ  cantly different, but the number of these patients 
precluded a powered analysis (Table 1).
The second induction trial, named GAIN (Gauging 
Adalimumab efﬁ  cacy in Inﬂ  iximab Nonresponders), was a 
4-week, placebo-controlled study which evaluated induction 
therapy with ADA in patients with moderate to severe 
CD who had either lost responsiveness or were intolerant to 
IFX (Sandborn et al 2007a).
Concurrent therapies, including stable dosages of 
5-aminosalicylates, corticosteroids and immunosuppressors, 
were permitted. A loss of response to IFX was deﬁ  ned in 
patients with a previous initial response (as deﬁ  ned by the 
investigator) to at least 2 doses of IFX 5 mg/kg or more every 
8 weeks, and who lacked improvement or had clinical wors-
ening at least 2 weeks after receiving the last dose of IFX. 
Therefore, it should be noted that the deﬁ  nition of loss of 
response may not reﬂ  ect the speciﬁ  c setting of daily clinical 
practice. Moreover, assessment of IFX failure in this study 
was retrospective rather than prospective, but a prospective 
assessment would have made enrollment difﬁ  cult.
The primary end-point was clinical remission at 
week 4, while secondary endpoints included 100- and 
70-point response, improvement in the number of draining 
ﬁ  stulas at week 4 (decrease 50% in the number of draining 
ﬁ  stulas at weeks 2 and 4 vs baseline) and ﬁ  stula remission at 
week 4 (closure of all ﬁ  stulas at weeks 2 and 4).
A total of 325 patients were randomized to receive 
ADA 160 mg at week 0 and 80 mg at week 2, or placebo at 
weeks 0 and 2 and followed through week 4.
At week 4, 21% (34 of 159) of patients in the ADA group 
compared with 7% (12 of 166) of patients in the placebo 
group achieved remission (p  0.001). The difference 
between the 2 groups was evident at week 1 for a decrease Biologics: Targets & Therapy 2008:2(4) 768
Cassinotti et al
of 70 points or more in the CDAI score; the rate of 70-point 
response at week 4 was greater in the ADA group than in 
the placebo group (52% vs 34%; p = 0.001). The rates of 
100-point response were also greater in the ADA group 
than in the placebo group at weeks 1, 2, and 4: 20% vs 12%, 
37% vs 18%, and 38% vs 25%, respectively. P values were 
not provided.
The beneﬁ  ts of ADA treatment remained unchanged 
when the results were stratiﬁ  ed for immunosuppressive 
therapy (Table 2), but not for corticosteroids, showing a 
clearly better response in patients receiving corticosteroids 
at baseline (Panes et al 2007).
Forty-ﬁ  ve patients (14%) of treated patients had draining 
enterocutaneous or perianal ﬁ  stulas at baseline. The rates of 
ﬁ  stula improvement and remission at week 4 were similar for 
both groups: 20% of patients in the placebo group vs 15% in 
the ADA group for improvement and 8% vs 5%, respectively, 
for remission. Once again, the number of patients was too 
small to obtain deﬁ  nitive conclusions.
The GAIN and CLASSIC-I studies suggest that, 
although the response in some patients treated with ADA is 
good, a signiﬁ  cant rate of subjects appear stably refractory 
to anti-TNF agents despite the shift from IFX to ADA, 
perhaps because of a shift to inﬂ  ammatory pathways less 
dependent on TNF. Moreover, it should be noted that the 
GAIN study does not provide important information about 
the IFX treatment used before enrollment, for example, the 
dosing schedule of IFX (episodic vs regular maintenance), 
disease activity before IFX treatment began, at the time of 
response, and at the time of loss of response, and the cumula-
tive dose of IFX before the loss of response or the develop-
ment of intolerance. Lacking this information, the GAIN trial 
may have introduced a bias against ADA by enrolling patients 
who otherwise would have been primary nonresponders. On 
the other hand, the trial might have included patients who 
would have responded well to IFX if treatment had been 
differently managed (increasing dosage or dosage frequency 
or changing dosing schedule), which could introduce a bias 
favoring ADA (Mannon 2007).
Randomized clinical trials: 
maintenance of response 
and remission
The CHARM trial (Crohn’s trial of the fully Human 
antibody Adalimumab for Remission Maintenance) was a 
phase III, randomized, double-blind, placebo-controlled, 
56-week study designed to compare two different regimens 
Table 1 Efﬁ  cacy of adalimumab (ADA) from subanalysis in ﬁ  stulizing disease and according to concomitant immunosuppressors in 
CLASSIC I for Crohn’s disease; outcome at 4 weeks (derived from Hanauer et al 2006)
Outcome Placebo ADA 40/20 ADA 80/40 ADA 160/80
Enterocutaneous or perianal 
ﬁ  stula improvement
33% 75% 20% 8%
Enterocutaneous or perianal 
ﬁ  stula remission
17% 75% 0% 0%
Remission in patients 
receiving immunosuppressors
9% 22% 10% 36%
Remission in patients not 
receiving immunosuppressors
13% 16% 30% 35%
Table 2 Efﬁ  cacy of adalimumab (ADA) 160/80 mg as induction therapy in GAIN trial for Crohn’s disease: remission in the overall 
population and in different subgroups of patients (derived from Sandborn et al 2007a)
Variable Adalimumab (%) Placebo (%)
Remission 21 7
Patients with previous loss of response to IFX 20 8
Patients with previous intolerance to IFX 22 5
Patients not receiving immunosuppressors at baseline 21 7
Patients receiving immunosuppressors at baseline 22 7
Patients not receving corticosteroids at baseline 15 10
Patients receving corticosteroids at baseline 33 4
Abbreviation: IFX, inﬂ  iximab.Biologics: Targets & Therapy 2008:2(4) 769
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of ADA maintenance therapy with placebo in patients with 
moderate to severe CD, including a subgroup previously 
treated with IFX, who responded to open-label induction 
with ADA 80 mg/40 mg (Colombel et al 2007a).
Concurrent therapies for CD, including stable dosages of 
5-aminosalicylates, corticosteroids and immunosuppressors 
were permitted. Patients who had received IFX or any other 
anti-TNF agent more than 12 weeks before screening was 
enrolled provided that they did not exhibit initial nonresponse 
to the agent. At enrollment, 47% of patients were receiving 
immunosuppressors (AZA, 6MP, MTX), and 50% had 
previously received a TNF-antagonist.
At week 0, all eligible patients received open-label 
ADA 80 mg followed by a 40-mg dose at week 2. At 
week 4, patients were randomized to one of 2 different 
dosages of ADA or placebo as maintenance treatment 
through week 56. Also at week 4, patients were stratiﬁ  ed by 
responder status (ie, whether or not they attained a decrease 
in CDAI of 70 points compared with baseline) and previ-
ous exposure to TNF antagonists. The co-primary efﬁ  cacy 
end points were clinical remission at weeks 26 and 56 for the 
randomized responders (ie, those with a 70-point response at 
week 4). A number of secondary endpoints were considered, 
including 70-point and 100-point response.
Of the 854 patients who received induction therapy, 
58% (499 patients) achieved a 70 points response at 
week 4 and were therefore randomized to receive 1 year 
of maintenance therapy with ADA 40 mg every other week 
(n = 260; 172 responders), ADA 40 mg weekly (n = 257; 
157 responders), or placebo (n = 261; 160 responders) 
through week 56. After randomization, patients experiencing 
a disease ﬂ  are (increase in CDAI of 70 points compared 
with week 4 and a CDAI score 220) or sustained non 
response (did not attain a CDAI decrease of 70 points 
compared with baseline) at or after week 12 were switched 
to open-label treatment with 40 mg ADA every other week; 
this dosage could be escalated to open-label treatment with 
40 mg weekly for those with continued non response or 
recurrent ﬂ  are.
Results at weeks 26 and 56 for randomized responders 
showed signiﬁ  cantly greater remission rates at both time 
points for patients who received maintenance therapy 
with ADA 40 mg every other week (40% at week 26; 
36% at week 56) or ADA 40 mg weekly (47% at week 26; 
41% at week 56) than for patients who received placebo 
(17% at week 26; 12% at week 56) (p  0.001 among the 
3 groups) (Figure 2). Statistically signiﬁ  cant (p  0.05) 
differences in remission rates between the ADA and placebo 
treatment arms were observed by week 6 and were sustained 
through week 56.
Pair-wise comparisons between each active treatment 
group and placebo were also statistically significant 
(p  0.001) for both 70-point and 100-point response at 
weeks 26 and 56 (Figure 2). There were no statistically 
signiﬁ  cant differences between the two ADA dosages for 
any of these endpoints.
It should be noted that, although uncontrolled remission 
rates at the end of the open-label induction phase 
were not a primary endpoint in CHARM, which was 
designed and powered to evaluate the efﬁ  cacy of ADA 
17
40
47
12
36
41
26
52 52
16
41
48
28
54 56
18
43
49
0
10
20
30
40
50
60
70
80
90
100
%
 
 
o
f
 
p
a
t
i
e
n
t
s
Remission 
week 26
Remission 
week 56
100-Reponse 
week 26
100-Reponse 
week 56
70-Reponse 
week 26
70-Reponse 
week 56
Placebo
ADA 40 mg every other week
ADA 40 mg weekly
Figure 2 Efﬁ  cacy of adalimumab (ADA) as a maintenance therapy for Crohn’s disease in the CHARM trial. Derived from Colombel et al (2007). p  0.001 for pairwise 
comparisons of each active treatment group vs placebo at all end points.Biologics: Targets & Therapy 2008:2(4) 770
Cassinotti et al
for maintenance therapy, the induction-loading dose 
regimen used (80 mg/40 mg) provided similar response 
rates (70-point decrease in CDAI of 58%) to both the 
80 mg/40 mg and 160 mg/80 mg regimens in CLASSIC I 
(59% for each regimen).
Among randomized responders, signiﬁ  cantly more ADA 
than placebo recipients achieved corticosteroid-free remission, 
with a rate of patients in corticosteroid-free remission at 
week 26 of 35% with ADA 40 mg every other week, 30% 
with ADA 40 mg weekly, and 3% with placebo (p  0.001 
for pair-wise comparisons vs placebo). Similar results were 
reported at week 56 for these parameters, with a cortico-
steroid-free remission rate of 29% with ADA 40 mg every 
other week, 23% with ADA 40 mg weekly, and 6% with 
placebo (p  0.001 for ADA 40 mg every other week vs 
placebo; p  0.008 for ADA 40 mg weekly vs placebo).
At week 26, 30% of ADA recipients (both groups 
combined) had complete ﬁ  stula closure compared with 13% 
of placebo recipients (p = 0.043), as in 33% and 13% for 
combined ADA groups and placebo group, respectively, at 
week 56 (p = 0.016). This is the main evidence currently avail-
able demonstrating any efﬁ  cacy of ADA in ﬁ  stulizing CD.
Subgroup analyses for randomized responders showed that 
clinical remission rates were greater among ADA than placebo 
recipients irrespective of concomitant immunosuppressive 
therapies (Table 3). However, rates of clinical remission at 
weeks 26 and 56 were numerically greater among patients 
naïve to anti-TNF therapy than among those who had received 
prior treatment with a TNF antagonist (Table 3).
The results of the CHARM trial, which had the largest 
sample size for a maintenance trial with ADA in CD, 
conﬁ  rm that this drug is more effective than placebo for 
long-term (56-week) maintenance of remission previously 
obtained with an induction regimen, even at the lower dose 
of 80/40 mg, which is the recommended dosage in clinical 
practice. The CHARM study, investigating the maintenance 
beneﬁ  t in those responding at week 4 of open-labeled adali-
mumab, also demonstrates some loss of response over the 
course of a year, although why this occurs is uncertain and 
may represent initial placebo responders to open-labeled 
treatment (Korzenik 2007).
A total of 276 patients who completed the 4-week 
CLASSIC-I trial entered a long-term extension study 
named CLASSIC-II (Sandborn et al 2007b). This was a 
randomized, placebo-controlled, maintenance follow-up trial, 
demonstrating that ADA 40 mg every other week or weekly 
was superior to placebo in maintaining remission for 1 year in 
patients with moderate to severe CD naïve to anti-TNF agents 
who achieved remission with ADA induction therapy.
Eligible patients (belonging to the pool of CLASSIC-I 
enrolled patients) were treated with ADA 40 mg at week 0 
(corresponding to week 4 of CLASSIC-I) and week 2. Those 
in remission at both week 0 and week 4 (n = 55) were 
randomized to receive ADA 40 mg every other week (n = 19), 
ADA 40 mg weekly (n = 18), or placebo (n = 18), through 
56 weeks.
At week 56, remission was maintained in 79%, 83%, and 
44% of patients in the respective groups (primary endpoint), 
with a statistically signiﬁ  cant difference between each ADA 
group and placebo (p  0.05). The 100-point response at 
week 56 was also better in ADA recipients (79% vs 89% 
vs 56%, respectively), as was the 70-point response rates 
(79% vs 89% vs 72%), although differences between groups 
were not statistically signiﬁ  cant.
CLASSIC-II also included an open-label arm in which 
patients who did not achieve remission at week 0 and 
Table 3 Remission rates stratiﬁ  ed by immunosuppressors use and previous TNF-antagonist experience, in CHARM for Crohn’s disease 
(derived from Colombel et al 2007)
Subgroup Placebo ADA 40 mg 
every other week
ADA 40 
weekly
Week 26
With immunosuppressors 16% 39% 44%
Withouth immunosuppressors 21% 42% 56%
Previous TNF-antagonist 16% 32% 42%
TNF-antagonist naïve 18% 47% 50%
Week 56
With immunosuppressors 12% 37% 39%
Withouth immunosuppressors 13% 33% 50%
Previous TNF-antagonist 10% 31% 34%
TNF-antagonist naive 14% 42% 48%Biologics: Targets & Therapy 2008:2(4) 771
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4 received ADA 40 mg every other week (n = 204), with 
dosage escalation permitted if necessary. A further 17 patients 
discontinued therapy at or before week 4 and were not evalu-
ated for efﬁ  cacy. At week 56, 46% of the 204 patients treated 
with open-label ADA were in clinical remission, 65% had a 
100-point response, and 72% had a 70-point response.
The efﬁ  cacy of ADA was not affected by the use or non 
use of immunosuppressive agents in either the open-label 
cohort or the randomized cohort.
It is relevant to note that the randomized part of the study 
included a highly selected group of patients who had rapidly 
responded to the drug (remission after 4 weeks of treatment) 
and had also shown the ability to maintain remission with 
further open-label treatment during an additional period of 
4 weeks before randomization. The 30 patients who achieved 
remission under treatment with ADA in the induction phase 
and were still in remission at week 56, represent 16.2% of the 
cohort of all patients who received active treatment during 
the entire study. Furthermore, these patients did not have 
sustained remission because corticosteroid withdrawal was 
mandatory in the randomized cohort, and 21% of patients 
treated with ADA and in remission at week 56 were receiving 
corticosteroids (Panes et al 2007).
Uncontrolled studies 
and case reports
In addition to the GAIN study, some smaller open label 
trials have been published conﬁ  rming the efﬁ  cacy of ADA in 
patients with active CD who lost responsiveness or developed 
intolerance to IFX (Sandborn et al 2004; Papadakis et al 2005; 
Anwar et al 2006; Peyrin-Biroulet et al 2006; Seiderer et al 
2007; Hinojosa et al 2007; Ho et al 2008).
In the largest of these trials, Hinojosa et al (2007) analyzed 
the outcome of 58 patients with moderate-severe CD (36 with 
luminal disease and 22 with ﬁ  stulizing disease; some with 
both disease types), who lost response or was intolerant to 
IFX, receiving an induction therapy with ADA 160/80 and 
followed up to 52 weeks. At week 4, patients with luminal 
disease achieved remission in 42% and 70-point clinical 
response in 83%. Of the 22 patients with ﬁ  stulizing disease, 
23% experienced ﬁ  stula remission (complete closure of all 
ﬁ  stulas that were draining at baseline), and 41% experienced 
ﬁ  stula improvement at week 4. Longer-term results are not 
available for this ongoing 52-week trial.
Seiderer et al used ADA as an induction and maintenance 
treatment for 16 patients with CD either refractory (n = 8) or 
intolerant (n = 8) to IFX. Patients received ADA 160/80 mg, 
followed by 80 mg every other week. In 10 of 16 patients (63%), 
remission was induced (n = 8) or maintained (n = 2) for at 
least 8 weeks. In 6 of these 10 patients ongoing remission was 
observed for more than 24 weeks (Seiderer et al 2007).
Sandborn et al assessed the tolerability and clinical 
beneﬁ  t of ADA in 24 patients with CD who had lost response 
or were intolerant to IFX, and were treated with ADA 
80/40 mg and then 40 mg every other week through 12 weeks. 
If patients did not achieve clinical remission, the dose was 
increased to 40 mg weekly. Of 17 patients with baseline 
active moderate-severe CD clinical, remission occurred at 
weeks 4 and 12 in 12% and 29%, respectively, while clinical 
response was achieved in 41% and 59%. Importantly, 79% of 
patients required to increase the dose of ADA during weeks 
4 to 6, thus increasing the cost of medication for the majority 
of patients (Sandborn et al 2004).
Papadakis et al have retrospectively reviewed 13 patients 
with active CD with attenuated response to IFX, who 
were treated with ADA over a 6-month period (Papadakis 
et al 2005). Induction treatment consisted of ADA 80/40 mg, 
followed by a maintenance regimen of  40 mg every other week. 
Fifty-four percent of patients had a complete response (deﬁ  ned 
as a Harvey-Bradshaw index (HBI) 4 and withdrawal 
of corticosteroid treatment); 31% had a partial response 
(decrease of 50% in HBI and tapering of corticosteroids 
to lower doses than used at the start of ADA treatment); and 
the remaining 15% were non responders. In 6 patients, the 
maintenance dose was increased in order to maintain clinical 
response: in 3 patients the dose was increased to 80 mg every 
2 weeks, in 2 patients to 80 mg every week, and in 1 to 120 mg 
every 2 weeks. About 73% of patients on concurrent cortico-
steroids were able to discontinue or signiﬁ  cantly decrease their 
dose of steroids. “Signiﬁ  cant decrease” was not deﬁ  ned in this 
paper, and it would be important to know how many patients 
were able to completely discontinue steroids.
Peyrin-Biroulet et al (2006) evaluated, in a 52-week 
open-label trial, the efﬁ  cacy and safety of ADA maintenance 
therapy in 24 CD patients who lost response to IFX (as judged 
by the investigator despite an increase of IFX dosage or of 
dosage frequency). The patients received an induction regimen 
of ADA 80/40 mg at week 0 and 2 respectively, and then 40 mg 
every other week. The primary efﬁ  cacy measure was clinical 
remission at week 52. Clinical remission rates were higher at 
weeks 4 (16/24, 67%) and 52 (14/24, 58%) compared with 
baseline (8/24, 35%) (p = 0.043 at week 52).
Recently, Ho et al (2008) have retrospectively reviewed 
the efficacy and safety of ADA in the clinical setting 
of patients with medically refractory CD treated with 
ADA in Edinburgh, over a 3-year period. Twenty-two Biologics: Targets & Therapy 2008:2(4) 772
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patients with CD, refractory or intolerant to corticosteroids 
and immunosuppressors, were treated using an 80⁄40 mg 
induction regimen followed by fortnightly 40 mg treatment. 
Twenty patients were previously treated with IFX: 36% had 
previous infusion reactions, 27% no response, and 14% lost 
response to IFX. Over a period of 1 year, 68% were in clinical 
remission and 67% avoided further surgery for active disease. 
However, 59% required dose escalation to 40 mg weekly. Of 
note, these authors for the ﬁ  rst time have shown that ADA can 
be effective in the primary non responders to IFX, although 
their number was very small; in fact, 3 (50%) primary non 
responders to IFX achieved remission.
Various other case reports and small pilot studies are 
also available indicating the successful and/or safe use of 
ADA for the treatment of CD during pregnancy (Vesga et al 
2005; Coburn et al 2006; Mishkin et al 2006), in pediatric 
patients (Mian and Baron et al 2005; Deslandres et al 2006; 
Hadziselimovic 2008), and in IFX-allergic patients (Youdim 
et al 2004; Stallmach et al 2004; Lester et al 2005). However, 
ADA is generally not recommended for use during pregnancy 
or lactation, and its efﬁ  cacy and safety have not yet been 
established in children.
A recent case report by Davis et al (2008) described the 
successful use of ADA in a 4-year child with CD and associ-
ated glycogen storage disease type Ib. This patient, who was 
refractory to conventional therapy, including G-CSF, and was 
intolerant to IFX, showed a complete clinical and endoscopic 
remission after 22 weeks of ADA treatment.
To date, no trials have examined the efﬁ  cacy of ADA 
for patients with extraintestinal manifestations, such as 
arthritis or uveitis, speciﬁ  cally occurring in the clinical 
setting of CD.
Safety
Apart of antibody-mediated reactions, such as infusion 
reactions, which are not expected with subcutaneous ADA, 
the safety concerns with ADA should be theoretically 
similar to what is seen with IFX. Moreover, the tolerability 
to ADA in patients with CD appears to be similar to that 
of other conditions for which the drug is approved, such 
as RA, although fewer long-term data are available from 
randomized trial and daily clinical practice.
Firstly, no patient died for drug-related causes. In the 
two short-term trials (CLASSIC-I and GAIN), serious 
adverse events were infrequent (1%–4%) and occurred 
in a similar percentage of ADA and placebo recipients 
(Hanauer et al 2006; Sandborn et al 2007a), including 
infections, CD worsening, and dehydration. The remaining 
adverse events that were reported by at least 5% of patients 
were site-injection reactions, abdominal tenderness, 
nausea, flatulence, nasopharyngitis, pharyngitis, and 
headache. Infections frequency was 16% in GAIN 
(Sandborn et al 2007a), while in CLASSIC-I it was 
10% (ADA 40 mg/20 mg), 17% (ADA 80 mg/40 mg), and 
21% (ADA 160 mg/80 mg), not dissimilar from placebo 
(Hanauer et al 2006). Serious adverse events were infrequent 
and occurred at similar frequencies in the ADA and placebo 
groups.
During the 4-week open-label induction phase of 
CHARM the most common adverse events were headache 
(5.9%) and nausea (5.3%). Serious adverse events were 
infrequent (5.3%) and included one case of multiple sclerosis. 
Infections occurred in 15.2%, and serious infectious adverse 
events occurred in 1.2% during this period (Colombel 
et al 2007a).
Tolerability data from the double-blind maintenance 
phase CHARM in general revealed the incidence of adverse 
events was similar between ADA and placebo groups, 
although there was a significantly greater incidence of 
infections and injection-site reactions in the ADA every 
other week arm, and a greater incidence of headache, fatigue, 
urinary tract infection, and injection-site reactions in the 
ADA every week arm, than in placebo recipients (Colombel 
et al 2007a). ADA was also generally well tolerated in 
CLASSIC-II (Sandborn et al 2007 b) and in the uncontrolled 
reports. In general the most frequent side effects with ADA 
are injection-site reactions. In GAIN they occurred in 11% 
of patients (Sandborn et al 2007a); in CLASSIC I they devel-
oped in 26% of patients in the ADA 40 mg/20 mg group, 
24% in the ADA 80 mg/40 mg group, and 38% of patients 
in the ADA 160 mg/80 mg group, compared with 16% of 
placebo recipients (Hanauer et al 2006); and in CHARM the 
incidence was 4.2% in the ADA every other week arm and 
5.8% in the ADA weekly arm (Colombel et al 2007a). Most 
are mild-to-moderate and diminish in frequency after the 
ﬁ  rst month of treatment. Erythema, pruritus, pain, burning 
sensation, and swelling have been described.
Over site-injection reactions, ADA has been associated 
with other, rare, cutaneous side effects. A case report by 
Boura et al (2006) has described the occurrence, 4 hours after 
a second infusion of ADA for refractory RA, of a violaceous 
plaque, emerging as an erythematous urticarial edema and 
associated with systemic manifestations (chest discomfort, 
epigastralgia, fever 38.4 °C, rigor, fatigue, and malaise), 
which was successfully treated with corticosteroids and 
antibiotics. Skin biopsy evaluation was consistent with the Biologics: Targets & Therapy 2008:2(4) 773
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rare diagnosis of eosinophilic cellulitis (Wells’ syndrome) 
(Boura et al 2006). Beuthien et al (2004) have also reported 
a patient with RA who developed an erythema multiforme-
like skin reaction to ADA. Within a few hours of the sixth 
injection of ADA, this patient developed papulopustular 
exanthema at the injection site on the thigh, as well as on 
both palms and soles, followed by desquamation of the skin 
of these areas. ADA was discontinued, and the exanthema 
rapidly improved.
Antinuclear antibodies (ANA) appear to be increased in 
patients treated with ADA, and clinical SLE-like syndromes 
have been reported in RA. The syndrome is reversible on 
cessation of the agent as with other TNF antagonists (Schiff 
et al 2006). In CLASSIC-II, of 185 patients assessed for ANA, 
172 were ANA-negative at baseline; among these, 33 (19%) 
have been found positive to ANA at week 56 or at their last 
visit; all of these 33 were positive to anti-dsDNA (Sandborn 
et al 2007b). In the comprehensive ADA clinical development 
programme for CD, investigators ascertained 3 cases of lupus 
or lupus-like syndrome with 1506 patient-years of exposure 
(Colombel et al 2007b). However, of note is the fact that 
not all these patients met accepted diagnostic criteria for the 
disease. Manosa et al (2008) have recently reported 2 cases 
of lupus induced in patients with CD treated with ADA. Both 
patients had been treated earlier with IFX and were nega-
tive for ANA before beginning IFX therapy. These patients 
became symptomatic of lupus and were ANA positive 1 and 
2 years, respectively, after initiating ADA therapy. Previous 
exposure to IFX may, however, be a potential risk factor for 
developing lupus when another anti-TNF agent is prescribed. 
It is not known, however, when these patients became ANA 
positive, as it appears these measurements were not conducted 
during or after IFX therapy nor before ADA use. In both cases, 
antidsDNA measurements were negative.
In a review of 233 cases of autoimmune diseases 
secondary to TNF-targeted therapies (IFX, ADA and 
etanercept) in 226 patients, Ramos-Casals et al (2007) found 
ADA to be involved in 21 cases, with vasculitis in 5 cases, 
SLE/lupus-like syndrome in 15 cases, and interstitial lung 
disease in 1 case.
Because there is a concern about the mycobacterial infec-
tions for patients treated with ADA, a PPD is mandated in 
the labeling of this agent. In addition most clinicians will 
also obtain a chest radiograph before therapy. Early studies 
in RA done with ADA suggested a dose–response relation-
ship with the occurrence of tuberculosis (Perez et al 2005). 
Patients who developed active tuberculosis were receiving 
higher doses than the licensed dose of 40 mg every other 
week. Reducing the treatment dose and screening for the 
presence of latent tuberculosis reduced the frequency of 
active tuberculosis to 1 to 2 cases in the next approximately 
2500 patients, although it did not eliminate the occurrence 
of tuberculosis completely.
No tuberculosis occurred during the CLASSIC-I and 
GAIN studies (Hanauer et al 2006; Sandborn et al 2007a), 
but in CHARM 2 patients treated with ADA developed 
pulmonary tuberculosis; of note, at baseline, they were 
puriﬁ  ed protein derivative-negative (PPD) and had normal 
ﬁ  ndings on chest radiographs, thus eroding the predictive role 
of the aforementioned screening (Colombel et al 2007a).
While data are not yet deﬁ  nitive, Furst et al (2006) argued 
that there is a lower incidence of latent tuberculosis activation 
after ADA (at doses used in the clinic) than IFX. Because 
the terminal half-lives, volumes of distribution, and clear-
ances of these 2 compounds are approximately equivalent, 
simple steady-state concentrations would not account for 
this difference. Since IFX is given intravenously and ADA is 
given subcutaneously, an important difference might be the 
difference in peak concentrations. At present, however, the 
speciﬁ  c role of pharmacokinetic differences in the activation 
of latent tuberculosis remainsspeculative.
Patients treated with anti-TNF-agents are at higher 
risk of opportunistic infection; cases of histoplasmosis, 
coccidioidomycosis, aspergillosis, nocardiosis, listeriosis, 
and pneumocystis, were described in patients on ADA in 
RA (Schiff et al 2006).
No malignancies or lymphomas were described in CD 
patients treated with ADA in controlled trials, but the limited 
follow up of all available studies precludes a correct judg-
ment. A case of locally advanced non-small cell lung cancer 
was reported in the serie by Ho et al (2008), developing in a 
70-year-old female high-smoker with CD colitis. This patient 
had been treated concurrently with oral MTX (also previ-
ously treated with IFX, parenteral MTX, and AZA) and was 
maintained in clinical remission with 40 mg weekly ADA 
therapy (92 weeks/1.7 years). However, a recent metanalysis, 
involving IFX and ADA combined, suggested an increase risk 
of lymphoproliferative diseases and malignancies in patients 
treated with these agents. The pooled odds ratio for malig-
nancy was 3.3, and the rate of malignancies was signiﬁ  cantly 
more common in patients treated with higher doses compared 
with patients who received lower doses of anti-TNF antibodies 
(Bongartz et al 2006).
Other rare side effects, described in RA, included 
medically signiﬁ  cant cytopenias and elevated transamines, 
which suggest that laboratory monitoring blood counts Biologics: Targets & Therapy 2008:2(4) 774
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and liver functions, at least intermittently, are useful 
(Scheinfeld 2005).
No trial has been performed to assess ADA for the 
treatment of congestive heart failure. However, due to the 
results of trials and post-marketing data with other TNF-alpha 
blockers, which show they can rarely worsen congestive 
heart failure (Kwon et al 2003), ADA should be avoided in 
these patients.
Both IFX and etanercept have been linked to demyelinating 
disease. Few data exist for ADA, but in CHARM a case of 
multiple sclerosis was reported in a patient treated with ADA 
(Colombel et al 2007a). The package insert of ADA notes the 
risk of neurological disease and explains that it should not be 
used in patients with such a disease and should be discontinued 
if such a disease occurs.
A comprehensive analysis of tolerability data from clinical 
trials with ADA, including 1506 patient-years of exposure 
in CD patients, showed that ADA was associated with a rate 
of 5.98 serious infections per 100-patient-years, including 
0.2 cases of tuberculosis per 100 patient-years (Burmester et at 
2006). The report, which is available only as an abstract, also 
showed rates of 0.07, 0.13, 0.07, and 0 per 100 patient-years 
for lymphomas, demyelinating disease, lupus-like syndromes, 
and congestive heart failure, respectively.
Finally, it should be mentioned that the needle included 
in the preﬁ  lled pen used for subcutaneous administration 
(see below) contains natural rubber (latex) which may cause 
allergic reactions in patients sensitive to latex.
The ongoing Adalimumab Crohn’s Safety Registry study 
(PYRAMID) is expected to enrol 5000 patients or more 
over 5 years, and should help provide additional insight into 
important clinical safety questions.
Immunogenicity
The formation of antibodies against monoclonal antibodies 
has been reported and this is the case for IFX, where, despite 
an active debate, they were associated with infusion reac-
tions and loss of efﬁ  cacy (Anderson 2005). In general, fully 
human monoclonal antibodies should be less immunogenic 
than chimeric monoclonal antibodies (Breedveld 2000) 
but it is difﬁ  cult to compare rates because immunogenicity 
analyses are product-speciﬁ  c (Anderson 2005). However, it 
should be pointed out that the concept that human proteins 
would be non immunogenic is not necessarily true. In fact, 
multiple examples exist of antibody formation to fully human 
therapeutic proteins, as in the case of recombinant human 
insulin, and fully human recombinant factor VIII clotting 
factor (Breedveld 2000).
Limited data are available on the development of 
antibodies to ADA in patients with CD, while more data 
are provided by RA studies. They clearly demonstrate that, 
despite the surrounding rationale to decrease immunogenicity 
while reducing the murine component of the drug, anti-ADA 
antibodies do develop. While ATIs are directed against 
the murine sequences in IFX, in the case of ADA they are 
directed against the variable binding region of the antibody 
(anti-idiotype antibodies).
In a pooled analysis of the results from the ADA 
trials in RA (http://www.fda.gov/cder/biologics/review/
adalabb123102r1p5.pdf), the rate of formation of anti-ADA 
antibodies was 5.5%, with lower percentages in patients 
treated with concomitant MTX (1% vs 12%). In CD, data 
from CLASSIC I reported that only 1 patient of 225 (0.04%) 
in the ADA 160 mg/80 mg group had a positive assay at 
week 2 with a subsequent negative assay at week 4 (Hanauer 
et al 2006); in GAIN, none of the 159 patients treated with 
ADA had positive results for anti-ADA antibodies at week 4 
(Sandborn et al 2007a). However, the presence of interfering 
measurable ADA and the short duration of these studies 
precluded a realistic analysis. More interesting data should 
come from long term studies: although immunogenicity was 
not evaluated in CHARM (Colombel et al 2007a), the occur-
rence of anti-ADA antibodies was evaluated among patients 
with CD in the CLASSIC-II maintenance study. During the 
52-week study, 2 of 54 patients (3.7%; 1 in the placebo group 
and 1 in the ADA every other week group) in the random-
ized arm and 6 of 215 patients (2.8%) in the open-label arm 
of the study were positive for anti-ADA antibodies. Of the 
269, 84 received concomitant immunosuppressors, none of 
whom were positive for anti-ADA antibodies (Sandborn 
et al 2007b).
Until now, no correlation was found between anti-ADA 
and clinical efﬁ  cacy and or adverse events.
Clinical use in Crohn’s disease
ADA is available in more than 70 countries and is approved in 
the US and EU for treating patients with RA, psoriatic arthri-
tis, and ankylosing spondylitis. In CD, ADA has received 
both FDA and EMEA approval with the following indica-
tions: 1) for reducing the signs and symptoms and inducing 
and maintaining clinical remission in adults with moderately 
to severely active CD who have had an inadequate response 
to conventional therapy, and 2) for reducing the signs and 
symptoms and inducing clinical remission in these patients 
if they have also lost response or are intolerant to IFX. 
Therefore, ADA is the second biologic therapy approved Biologics: Targets & Therapy 2008:2(4) 775
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for the treatment of patients with moderately to severely 
active CD.
ADA also seems effective in maintaining corticosteroid-
free remission and obtaining complete fistula closure 
(although no published trial has used these as primary 
endpoints).
ADA is administered by subcutaneous injection, as 
commercially available prefilled pen (HUMIRA Pen) 
containing 0.8 mL (40 mg) of drug.
The recommended ADA induction dose regimen for 
adult patients with moderate-severe CD is usually 80 mg 
at week 0 followed by 40 mg at week 2. In case there is a 
need for a more rapid response to therapy, the regimen with 
160 mg at week 0 (dose can be administered as 4 injections 
in one day or as 2 injections per day for 2 consecutive 
days) and 80 mg at week 2 can be used with the awareness 
that the risk for adverse events is higher during induction. 
After induction treatment, the recommended dose is 40 mg 
every other week via subcutaneous injection as maintenance 
treatment.
For induction treatment, ADA should be given in 
combination with corticosteroids. ADA can be given as 
monotherapy in case of intolerance to corticosteroids or when 
continued treatment with corticosteroids is inappropriate.
The use of ADA in CD beyond 1 year has not been 
evaluated in controlled clinical studies.
The results from the available trials suggest that 
concomitant immunosuppressive therapies do not inﬂ  uence 
response. This interaction, as well as the influence of 
immunosuppressant medication on antibody formation, needs 
to be addressed further in future clinical trials.
ADA is administered subcutaneously; this can be 
an important resource for patients who have difficult 
venous access, and may avoid intravenous catheters. 
Self-administration may complicate the possibility to monitor 
the adherence to the therapy. On the other hand this route 
may make the patients active protagonist of own care, thus 
increasing compliance. Moreover, self-administration can 
decrease indirect costs, such as recruitment of medical 
practitioners or time lost from work.
A final question that requires more attention is the 
appropriate induction doses for ADA (160 mg/80 mg 
or 80 mg/40 mg). This should be taken in account when 
determining their inﬂ  uence on costs and safety. In this 
regard, the data of Ho et al (2008) show that nearly 60% of 
patients required dose escalation to 40 mg weekly within 
6 months of therapy. Weekly ADA has substantial differential 
cost implications and this needs to be factored into the 
pharmacoeconomic analyses for funding or regulatory bodies 
of healthcare provision.
Economic analyses of ADA in CD are not available. 
When weighing the risks and beneﬁ  ts of biologic therapy 
for patients with IBD, physicians must account for the 
consequences of undertreated IBD. These include the direct 
costs of hospitalizations and operations for IBD, the direct 
costs of treatment for side effects associated with chronic, 
non-biologic therapies, and indirect costs associated with lost 
productivity or non-monetary costs such as quality-of-life 
decrements. It is noteworthy to highlight also that Kaplan 
et al (2007) recently showed that in patients who have 
lost response to IFX, dose escalation will yield more 
quality-adjusted life-years compared to switching to ADA; 
however, at a considerable cost, although it should be noted 
that in the ADA strategy, the drug was initiated with a 
160 mg injection followed by an 80 mg dose 2 weeks later 
with subsequent maintenance of 40 mg every other week, 
thus further increasing the costs.
ADA will compete with IFX at this stage in treatment. 
Currently, head-to-head comparisons among anti-TNF agents 
do not exist, in part because of the large sample size required 
to demonstrate either differences between, or equivalence 
of, treatments. In the absence of these data, claims that one 
drug is better than the others have been met with scepticism 
by practising physicians. Comparative costs will depend on 
local procedures for use of TNF-alpha inhibitors.
The clinical setting of use for ADA, and its efﬁ  cacy, 
appears to be similar to that of IFX, with some advantages, 
but some unanswered questions remain that will need to 
be addressed. Randomized clinical trials have shown that 
ADA can induce and maintain clinical remission in patients 
with moderately to severely active CD, both IFX-naïve 
and secondarily refractory or intolerant to IFX. The current 
availability of multiple TNF-neutralizing antibodies is highly 
desirable. As all the currently available TNF-neutralizing 
antibodies are immunologically unique, patients who start 
failing to respond to treatment with one of these biologics can 
be switched to one of the others, greatly enhancing clinical 
care (Peppelenbosch 2007).
The obvious advantage of ADA compared to IFX is the 
route of administration – subcutaneous, which will allow 
patients to self administer this medication. This less intrusive 
method of drug delivery will be very much appreciated by 
most patients. The safety and tolerability of ADA should be 
similar to that of IFX in most possible side effects, but more 
long-term data are needed. Immunogenicity is another ﬁ  eld 
that requires more studies about the frequency, risk factors Biologics: Targets & Therapy 2008:2(4) 776
Cassinotti et al
for development, and impact of antibody formation against 
ADA in patients with CD.
Although certain details about the optimal way to 
use ADA for the management of CD exist, undoubtedly 
this subcutaneously administered anti-TNF medication 
will play a crucial role in treating patients with CD 
(Bressler 2007).
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